CureVac NV (CureVac NV) Change In Receivables : $-12.27 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is CureVac NV Change In Receivables?

CureVac NV's change in receivables for the quarter that ended in Mar. 2024 was $-0.11 Mil. It means CureVac NV's Accounts Receivable increased by $0.11 Mil from Dec. 2023 to Mar. 2024 .

CureVac NV's change in receivables for the fiscal year that ended in Dec. 2023 was $-8.81 Mil. It means CureVac NV's Accounts Receivable increased by $8.81 Mil from Dec. 2022 to Dec. 2023 .

CureVac NV's Accounts Receivable for the quarter that ended in Mar. 2024 was $15.92 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. CureVac NV's Days Sales Outstanding for the three months ended in Mar. 2024 was 108.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. CureVac NV's liquidation value for the three months ended in Mar. 2024 was $91.87 Mil.

CureVac NV Change In Receivables Historical Data

The historical data trend for CureVac NV's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Change In Receivables Chart

CureVac NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-11.24

18.65

-18.85

10.07

-8.81

CureVac NV Quarterly Data
	Mar19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															3.38	-0.78	-4.30	-7.08	-0.11

CureVac NV Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.27 Mil.

CureVac NV (NAS:CVAC) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

CureVac NV's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	15.917	/	13.449	*	91
=	108.00

2. In Ben Graham's calculation of liquidation value, CureVac NV's accounts receivable are only considered to be worth 75% of book value:

CureVac NV's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	330.386	-	264.695	+	0.75 * 15.917	+	0.5 * 28.486
=	91.87

CureVac NV Change In Receivables Related Terms

Thank you for viewing the detailed overview of CureVac NV's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

CureVac NV (CureVac NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (NAS:CVAC) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

CVAC:Mexico 1CVAC:Italy 0A9E:UK 5CV:Germany CVAC:Austria

Address

Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.curevac.com

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.